Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Average Recommendation of “Hold” from Analysts

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been assigned an average rating of “Hold” from the five analysts that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $3.33.

A number of equities analysts have recently weighed in on the company. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, StockNews.com started coverage on Syros Pharmaceuticals in a research report on Tuesday, December 31st. They issued a “sell” rating for the company.

Insider Activity at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the transaction, the director now owns 41,070 shares in the company, valued at $11,088.90. This represents a 76.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SYRS. GSA Capital Partners LLP bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth $34,000. Acadian Asset Management LLC boosted its stake in Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares during the period. Certuity LLC bought a new position in Syros Pharmaceuticals in the 2nd quarter worth about $109,000. Finally, Exome Asset Management LLC boosted its stake in Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares during the period. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Price Performance

Syros Pharmaceuticals stock opened at $0.26 on Thursday. The stock has a market capitalization of $7.02 million, a price-to-earnings ratio of -0.09 and a beta of 1.31. Syros Pharmaceuticals has a 52-week low of $0.18 and a 52-week high of $7.98. The stock’s 50 day moving average price is $0.79 and its two-hundred day moving average price is $2.49. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same period last year, the business earned ($1.35) EPS. On average, equities analysts predict that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.